Literature DB >> 18831062

Genotype-phenotype relationship for localization and age distribution of telangiectases in hereditary hemorrhagic telangiectasia.

Tom G W Letteboer1, Hans-Jurgen Mager, Repke J Snijder, Dick Lindhout, Hans-Kristian Ploos van Amstel, Pieter Zanen, Kees J J Westermann.   

Abstract

Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant disease characterized by arteriovenous malformations (AVMs) ranging from telangiectases to larger AVMs. Mutations in two genes cause HHT; ENG (HHT1) and ACVRL1 (HHT2). Although the hallmark for clinical diagnosis is the presence of telangiectases, there are few publications reporting the relative distribution and frequency of these features between HHT1 and HHT2. Here, the results of such analysis of telangiectases in 268 patients with HHT1 and 130 patients with HHT2 are described. Localization of the telangiectases is reported, and patients were clustered by age to estimate the site prevalence for different age categories. We show that telangiectases of the nasal mucosa are present at a higher prevalence and start to appear earlier in life than those of the oral mucosa or dermal sites in patients with either HHT1 or HHT2. Oral and nasal mucosal telangiectases are present earlier in life in patients with HHT1 compared to patients with HHT2, whereas dermal lesions are more frequent and appear earlier in life in patients with HHT2. In patients with either HHT1 or HHT2, the number of sites affected increases with age. In patients with HHT1, more women than men had skin telangiectases, particularly on the face. These results confirm that the frequency of AVMs differ between patients with HHT1 and HHT2, and that these differences can be detected on physical examination. Copyright 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18831062     DOI: 10.1002/ajmg.a.32243

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  23 in total

1.  An evaluation of the severity and progression of epistaxis in hereditary hemorrhagic telangiectasia 1 versus hereditary hemorrhagic telangiectasia 2.

Authors:  Benjamin N Hunter; Benjamin H Timmins; Jamie McDonald; Kevin J Whitehead; P Daniel Ward; Kevin F Wilson
Journal:  Laryngoscope       Date:  2015-09-15       Impact factor: 3.325

Review 2.  Hereditary hemorrhagic telangiectasia.

Authors:  Anne Grand'Maison
Journal:  CMAJ       Date:  2009-04-14       Impact factor: 8.262

3.  Whole-Body Distribution and Clinical Association of Telangiectases in Systemic Sclerosis.

Authors:  Mathieu Jouvray; David Launay; Sylvain Dubucquoi; Vincent Sobanski; Céline Podevin; Marc Lambert; Sandrine Morell-Dubois; Hélène Maillard; Pierre-Yves Hatron; Eric Hachulla; Jonathan Giovannelli
Journal:  JAMA Dermatol       Date:  2018-07-01       Impact factor: 10.282

Review 4.  Hereditary hemorrhagic telangiectasia of the liver complicated by ischemic bile duct necrosis and sepsis: case report and review of the literature.

Authors:  Anastasios Mavrakis; Anthony Demetris; Erin Rubin Ochoa; Mordechai Rabinovitz
Journal:  Dig Dis Sci       Date:  2009-09-16       Impact factor: 3.199

5.  VEGF neutralization can prevent and normalize arteriovenous malformations in an animal model for hereditary hemorrhagic telangiectasia 2.

Authors:  Chul Han; Se-Woon Choe; Yong Hwan Kim; Abhinav P Acharya; Benjamin G Keselowsky; Brian S Sorg; Young-Jae Lee; S Paul Oh
Journal:  Angiogenesis       Date:  2014-06-24       Impact factor: 9.596

Review 6.  Differential diagnosis of hepatopulmonary syndrome (HPS): Portopulmonary hypertension (PPH) and hereditary hemorrhagic telangiectasia (HHT).

Authors:  Inna Krynytska; Mariya Marushchak; Anna Mikolenko; Anzhela Bob; Iryna Smachylo; Ludmyla Radetska; Olga Sopel
Journal:  Bosn J Basic Med Sci       Date:  2017-11-20       Impact factor: 3.363

7.  Mutational and phenotypic characterization of hereditary hemorrhagic telangiectasia.

Authors:  Claire L Shovlin; Ilenia Simeoni; Kate Downes; Zoe C Frazer; Karyn Megy; Maria E Bernabeu-Herrero; Abigail Shurr; Jennifer Brimley; Dilipkumar Patel; Loren Kell; Jonathan Stephens; Isobel G Turbin; Micheala A Aldred; Christopher J Penkett; Willem H Ouwehand; Luca Jovine; Ernest Turro
Journal:  Blood       Date:  2020-10-22       Impact factor: 22.113

8.  Somatic Mutations in Vascular Malformations of Hereditary Hemorrhagic Telangiectasia Result in Bi-allelic Loss of ENG or ACVRL1.

Authors:  Daniel A Snellings; Carol J Gallione; Dewi S Clark; Nicholas T Vozoris; Marie E Faughnan; Douglas A Marchuk
Journal:  Am J Hum Genet       Date:  2019-10-17       Impact factor: 11.025

9.  Update on molecular diagnosis of hereditary hemorrhagic telangiectasia.

Authors:  Jennifer Richards-Yutz; Kathleen Grant; Elizabeth C Chao; Susan E Walther; Arupa Ganguly
Journal:  Hum Genet       Date:  2010-04-23       Impact factor: 4.132

10.  Pazopanib for severe bleeding and transfusion-dependent anemia in hereditary hemorrhagic telangiectasia.

Authors:  Joseph G Parambil; James R Gossage; Keith R McCrae; Troy D Woodard; K V Narayanan Menon; Kasi L Timmerman; Douglas P Pederson; Dennis L Sprecher; Hanny Al-Samkari
Journal:  Angiogenesis       Date:  2021-07-22       Impact factor: 9.596

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.